Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Heart Failure, Congestive
Interventions: GSK2798745 Micronized API without SLS and hypermellose (Tablet A), GSK2798745 Micronized API with SLS and hypermellose (Tablet B), GSK2798745 milled API without SLS and hypermellose (Tablet C); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Febrile Infection, Anthrax
Interventions: TaqMan Bacillus anthracis Detection Kit; Device
Lead sponsor: MRI Global; Industry
Eligibility: 2 Years to 89 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Tarpon Springs, Florida • Fall River, Massachusetts • Franklin, Massachusetts

Conditions: Colorectal Cancer
Interventions: Standard Inspection Colonoscopy, Dual Inspection Colonoscopy; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 768 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy
Interventions: Phenytoin (Ascoli), Phenytoin (Vega Baja); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Epic Research & Diagnostics, Inc.; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona

Conditions: NAFLD, Obesity, Nutritional and Metabolic Diseases
Interventions: Time restricted eating; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 25 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Davis, California

Conditions: Type 2 Diabetes
Interventions: Ghrelin, Saline; Drug · Other
Lead sponsor: Jenny Tong, MD, MPH; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Coronary Artery Disease
Interventions: low-dose stress MPI SPECT; Other
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity
Interventions: Daily Caloric Restriction (DCR), Intermittent Fasting (IMF); Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Obesity
Interventions: Eucalaloric feeding, Acute Fasting, Acute Overfeeding; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Volunteers
Interventions: AG-348, [13C6]AG-348; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Leukemia, Myeloid, Chronic
Interventions: LBH589; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Duarte, California • Aurora, Colorado • Denver, Colorado + 13 more

Conditions: Pharmacokinetics
Interventions: Proellex; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Dietary Intervention, Educational Intervention, Electronic Health Record Review, Interview, Nutritional Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Thyroid Cancer
Interventions: Lenvatinib, Lenvatinib matching placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: La Jolla, California • San Diego, California • Torrance, California + 11 more

Conditions: Glioblastoma
Interventions: Temodar and Irinotecan; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Bipolar Disorder
Interventions: Not listed
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Beachwood, Ohio • Cleveland, Ohio

Conditions: Lethal Means Safety, Brief Intervention, Concern Significant Others
Interventions: The Family Firearms Secure storage Training (FFAST) Intervention, Health and Stress Counseling; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Atrial Fibrillation
Interventions: KODEX - EPD; Device
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Obesity
Interventions: Standard of Care, Time Restricted Eating; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Healthy
Interventions: Oxycodone, Naltrexone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Lansoprazole, Prevacid®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Lysosomal Acid Lipase Deficiency
Interventions: Sebelipase Alfa; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Up to 8 Months
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy Volunteers
Interventions: 30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets

Febrile Whole Blood Specimen Collection and Testing

A Comparison of Methods to Detect Polyps During Colonoscopy

A Study to Learn How Different Forms of The Study Medicine Called Phenytoin Are Taken up Into the Blood in Healthy Adults

Metabolic Syndrome Feasibility Study

The Effect of Time-restricted Eating on Liver Metabolism

Preprandial Ghrelin Effect

Rapid Stress/Rest Single-Day Tc-99m Sestamibi Myocardial Single Photon Emission Computed Tomography

Intermittent Fasting Versus Daily Caloric Restriction for Weight Loss

Thermogenenic Responses to Fasting and Overfeeding in Women

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

Crossover Study of the Safety and PK Properties of Proellex®

Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide

Understanding Treatment Adherence Among Individuals With Rapid Cycling Bipolar Disorder

Testing Family Firearm Secure Storage Training (FFAST) to Prevent Suicide

All Inclusive Kodex - EPD Study

Effect of Time-restricted Eating on Catecholamine-sensitivity of Adipose Tissue in Obese Adults

Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers

Lansoprazole 30 mg DR Capsule Fasting Study

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants